Abstract:Objective This study evaluated the efficacy and safety of tacrolimus(FK506) as secondary intervention in cyclosporine A(CsA) treated renal transplantation patients with chronic allograft nephropathy(CAN).Methods Sixty-one patients who received a cadeveric renal transplantation in our unit more than 12 months prior to study enrollment and who were being treated with CsA-based immunosuppressive treatment were included,all patients received allograft biopsy and were diagnosed as CAN according to Banff criteria.Patients were differentiated according to following regimen.Patients were either converted to FK506 group(n=31) or remained on their initial CsA-based immunosuppression(CsA group,n=30).An important effectiveness index is the rate of decline of renal function before and after the FK506 conversion,calculated by curve fitting and regression analysis with reciprocal SCr as Y-axis and time as X-axis.Therapeutic effectiveness is defined as improvement or stabilization of renal function.Improvement: slope of serum creatinine less than-5%;Stabilization: slope of serum creatinine between -5% and 5%;Deterioration of renal function: slope of serum creatinine larger than 5%.Results Trough TC,TG and LDL levels remained unchanged in CsA group while statistically reduced in FK506 group.Renal function was markedly improved in FK506 group.Among the twenty-four patients with improvement in the rate of decline of renal function,twenty patients(64.5%) had their regression lines become positive and four patients(12.9%) had their regression lines become less negative.Seven patients(22.6%) had increased rate of decline in renal function with their regression lines becoming more negative.The clinical efficiency after the FK506 conversion for 31 patients was compared with the pathological degree of allograft nephropathy before the conversion,and the lighter the pathological degree was,the higher the improvement rate of renal function was,and vice versa.Graft survival rate was significantly increased in FK506 group(93.5% vs 76.7%,P0.01) follow-up one year.The incidence rates of hypertension,hypertrichosis,gum hypertrophy,liver disfunction,and CMV pneumonia in FK506 group were markedly lower than those in CsA group,63.8% vs 84.6%(P0.01),22.4% vs 53.8%(P0.01),8.6% vs 51.3%(P0.01),6.5% vs 16.7%(P0.01) and 6.5% vs 10.0%(P0.05),respectively.Conclusion FK506 treatment markedly improved abnormality in lipid profile and graft renal function post-transplantation.Conversion from a CsA-based regimen to a tacrolimus-based regimen was an effective alterative for salvage of patients with abnormal graft renal function induced by CAN.

Clinical application of CsA substituted by FK506 in renal allograft recipients with hepatic and/or renal dysfunction

Clinical Study on the Use of FK506 after Renal Transplantation

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Clinical Application of FK506 in Renal Transplantation

Clinical effect of FK506 on the treatment of steroid-resistant rejection after kidney transplantation

Clinical comparison of tacrolimus and CsA in end stage renal disease of diabetic renal allograft recipients

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

Conversion from Cyclosporine to Tacrolimus in Renal Allograft Recipients with Chronic Allograft Nephropathy: A Prospective Single Center Study

Application of Tacrolimus in 862 Renal Transplantation Recipients

[Application of Tacrolimus and Cyclosporine A in HBV-carrying Renal Transplant Recipients].

The Effects Comparison of FK506 and CsA on Serum Lipids in Renal Allograft Recipients

Long-term Evaluation of FK506 Based Immunosuppressive Therapy in Kidney Transplantation

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease]

Assessment of Cyclosporine A Withdrawal in Renal Allograft Transplant Recipients

The Use of Tacrolimus in 932 Renal Transplant Recipients

Clinical Analysis on Conversion from Tacrolimus to Cyclosporine A in Recipients of Liver Transplantation

CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Effect of Tacrolimus As Rescue Therapy in Patients with Acute Accelerating Allograft Renal Rejection

Conversion from Cyclosporine to Tacrolimus for the Treatment of Chronic Allograft Nephropathy